Revista Newslab Edição 164

newslab.analytica

Revista Newslab Edição 164 - Março 2021

eceptors, que reconhecem diferentes

padrões moleculares associados à vírus

chamados de PAMPs, do inglês Pathogen

Associated Molecular Pathern

(Vabret et al., 2020).

Um ponto chave que merece ser

destacado é o desenvolvimento de

vacinas contra o SARS-CoV-2 em

instituições nacionais utilizando plataformas

tecnológicas de nova geração

como o RNA replicante, vacina

proteica recombinante e vacina sintética

em ensaios de fase pré-clínica.

Considerações Finais

Desde a antiguidade, o desenvolvimento

das vacinas de forma empírica

e atualmente com comprovação

científica remetem ao uso dos

animais de laboratório nas pesquisas

em seus ensaios pré-clínicos e

suas sucessivas etapas com grupos

controles e experimentais. A corrida

biotecnológica para o avanço de

novas técnicas possui um objetivo

único – de prevenir e controlar a

atual pandemia que assola a humanidade

e reporta cronologicamente

as condições sanitárias de épocas

históricas. O conhecimento adquirido

e aplicado evidencia a fusão

de ideias na tentativa de alcançar

a equidade vacinal no bem comum

da saúde coletiva.

Referências

Alharbi et al. ChAdOx1 and MVA based vaccine candidates

against MERS-CoV elicit neutralising antibodies

and cellular immune responses in mice. Vaccine. 2017

Jun 27; 35(30): 3780–3788. doi: 10.1016/j.vaccine.2017.05.032

Barth, O.M., Simões, R.S.Q. Vírus emergentes e reemergentes.

In: Virologia Humana e Veterinária. 1.ed. Rio de

Janeiro, p:317 – 324, 2019.

Coronaviridae study group of the international committee

on taxonomy of viruses. The species severe accurate

respiratory syndrome related coronavirus: classifying

2019n-CoV and naming it SARS-CoV-2. Nature

Microbiology: 5536-544, 2020.

Folegatti,P.M et al. Safety and immunogenicity of a

candidate Middle East respiratory syndrome coronavirus

viral-vectored vaccine: a dose-escalation,

open-label, non-randomised, uncontrolled, phase 1

trial . Lancet Infect Dis 2020 20: 816-26 https://doi.

org/10.1016/ S1473-3099(20)30160-2.

Folegatti, P.M et al. Safety and immunogenicity of the

ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminar

reporto f a phase 1/2 single-blind, randomised

controlled trial. Lancet 2020: 396:467-78. https://doi.

org/10.1016/ S0140-6736(20)31604-4.

Gao et al. Development of na inactivated vaccine candidate

for SARS-CoV-2.Science 369, 77–81 (2020).

Garry,R.F. Mutations arising in SARS-CoV-2 spike on

sustained human-to-human transmission and human-to-animal

passage. Virological.org, 2021.

Jackson, L.A et al. Na mRNA vaccine Against SARS-CoV-2

– preliminar report. The New England Journal of Medicine

2020;383:1920-31. doi: 10.1056/NEJMoa2022483.

Keech, C., et al. First-in-human trial of a SARS-CoV-2

recombinant spike protein nanoparticle vaccine. doi:

https://doi.org/10.1101/2020.08.05.20168435.

Li, Y., Wang, H., Tang, X., Ma, D., Du, C., et al., Potential

host range of multiple SARS-like coronaviruses and an

improved ACE2-Fc variant that is potent against both

SARS-CoV-2 and SARS-CoV-1. BioRxiv, 2020, doi.

org/10.1101/2020.04.10.032342.

Mulligan, M.J et al. Phase 1/2 study to describe the

safety and immunogenicity of a COVID-19 RNA vaccine

candidate (BNT162b1) in adults 18 to 55 years of age:

interim report. MedRxiv, 2020. doi: https://doi.org/10.

1101/2020.06.30.20142570.

Nunes et al. Invasion Science and the Global Spread of

SARS-CoV-2. Trends in Ecology & Evolution,2020, 35:8

Pohlmann, S., Del Val, M., Jaimes, J., Decroly, E., Li, F.,

Bowman, G. CCU CGG CGG GCA. As doze letras que

mudaram o mundo. El País, 2020.

Rodriguez-Morales et al. History is repeating itself:

Probable zoonotic spillover as the cause of the 2019

novel Coronavirus Epidemic. Le Infezioni in Medicina,

1:3-5, 2020.

Rodrigues, L, 2020. Conheça as 5 maiores pandemias

da história. https://revistagalileu.globo.com. Acesso

em 21/02/2021.

Sanar. Pandemias na História: o que há de semelhante

e de novo na Covid-19. https://www.sanarmed.com.

Acesso em 21/02/2021.

Simões, R.S.Q. Animal and Human Coronavirus Disease.

COJ Technical & Scientific Research, 2 (5), CO-

JTS.000547.2020, 2020.

Simões, R.S.Q.S. Coronavírus: SARS-CoV, MERS-CoV

e SARS-CoV-2. In: Saúde do Ensino à pesquisa. Ed.

Pasteur - vol.1, p:191-203, ISBN:978-65-86700-07-7.

https://doi.org/10.29327/522782.

Simões, R.S.Q.S et al. Computacional modeling in virus

infections and virtual screening, docking and molecular

dynamics in drug design. Networks in systems biology

- applications for disease modeling, Ed. Springer.

https://doi.org/10.1007/978-3-030-51862-2_12.

Sironi et al. SARS-CoV-2 and COVID-19: A genetic, epidemiological,

and evolutionary perspective. Infection,

Genetics and Evolution 84 104384, 2020. https://doi.

org/10.1016/j.meegid.2020.104384.

Thanh Le et al. The COVID-19 vaccine development

landscape Tung. Nature Reviews 19: 305, 2020.

Vabret, N., Britton, G.J., Gruber, C., Hegde, S., Kim, J.,

Kuksin, M., Levantovsky, R et al. Immunology of CO-

VID-19: current state of the science. Immunity, 2020,

doi: https://doi.org/10.1016/j.immuni.2020.05.002.

Van Doremalen, N., et al. A single dose of ChAdOx1

MERS provides protective immunity in rhesus macaques.

Sci. Adv. 2020; 6: eaba8399

Van Riel, P & Wit, E. Next-generation vaccine platforms

for COVID-19. Nature Materials | VOL 19 | August 2020 |

810–820 | www.nature.com/naturematerials

Voysey, M et al. Safety and efficacy of the ChAdOx1

nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim

analysis of four randomised controlled trials in Brazil,

South Africa, and the UK. Lancet 2021; 397: 99–111

https://doi.org/10.1016/ S0140-6736(20)32661-1.

Yan, R., Zhang, Y., Li, Y., Xia, L., Guo, Y., Zhou, Q. Structural

basis for the recognition of the SARS-CoV-2 by full

lengh human ACE-2. Science, 2020.

Zhu et al. Safety, tolerability, and immunogenicity of

a recombinant adenovirus type-5 vectored COVID-19

vaccine: a dose-escalation, open-label, non-randomised,

first-in-human trial. Lancet 2020; 395: 1845–54.

https://doi.org/10.1016/ S0140-6736(20)31208-3.

ARTIGO CIENTÍFICO I

Revista NewsLab | Março 2021

0 23

More magazines by this user
Similar magazines